We are accepting applications for our annual Turning the Tide Ovarian Cancer Retreats, Inc. This year, it will be held at Camp Medomak, located in Washington, ME. from Monday June 17th to Friday, June 21. Medomak is located on the shores of Washington Pond, about 30 minutes from the coastal towns of Rockland, Camden READ MORE
Author: Margaret Mastrangelo
Ovations for the Cure: The NEW View with Elle Simone Scott
JOIN US AT THE VIEW! SATURDAY APRIL 20, 2024 AT 1pm Join us at the NEW View Boston atop the Prudential Center for an afternoon of cocktails, light lunch and dancing at Ovation’s NEW Signature Event! Your host for the afternoon is Elle Simone Scott, an ovarian cancer thriver, advocate, and a familiar face from READ MORE
Ovations for the Cure: NEW View Boston from the Top
JOIN US AT THE VIEW! SATURDAY, APRIL 20, 2024 AT 1PM Join us at the NEW View Boston atop the Prudential Center for an afternoon of cocktails, light lunch and dancing at Ovation’s NEW Signature Event! Your host for the afternoon is Elle Simone Scott, an ovarian cancer thriver, advocate, and a familiar face READ MORE
2023 TTT Slideshow
Turning the Tide 2023 – spidercurran
16th Annual Learning for Living Symposium
Save the date! More information to come soon. Click here for more details and to sign-up!
Olaparib Treatment Before Surgery Proves Feasible in BRCA-Mutant Ovarian Cancer
Neoadjuvant treatment with olaparib prior to surgical resection and adjuvant chemotherapy was well tolerated and led to a 100% optimal resection rate in patients with newly diagnosed, BRCA-mutant ovarian, primary peritoneal, or fallopian tube cancer.
This is an edited version of an article by Carolyn Seymour published in OncLive Mar. 28, 2023
COM701 Plus BMS-986207/Nivolumab Shows Early Activity in Platinum-resistant Ovarian Cancer
A triplet regimen comprised of COM701, BMS-986207, and nivolumab (Opdivo) was found to have encouraging antitumor activity and favorable tolerability in patients with heavily pretreated, platinum-resistant ovarian cancer.
This is an edited version of an article by Ryan Scott published in OncLive Jan. 12, 2023
Dana-Farber Research Supports FDA Approval of New Therapy for Certain Patients with Ovarian Cancer
Mirvetuximab soravtansine has been approved by the FDA for the treatment of recurrent platinum-resistant high-grade serous ovarian cancer that highly expresses the folate receptor alpha. Clinical testing of this new therapy has been co-led by Dr Ursula Matulonis, MD.
This is an edited version of a news release published by Dana Farber Cancer Institute on Nov. 14, 2022
FDA Approves Mirvetuximab Soravtansine For Treatment of Ovarian Cancer
On November 14, 2022, the FDA granted accelerated approval to mirvetuximab soravtansine for the treatment of adult patients with folate receptor α (Frα)–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received 1 to 3 prior systemic treatment regimens.
This is an edited version of an article written by Caroline Seymour and published in OncLive Nov. 15, 2022